Камостат мезилат (Camostat mesylate)
Международное непатентованное наименование
Камостат мезилат (Camostat mesylate)
Торговое наименование
-
Производитель, страна
Towa Pharmaceutical, Japan
Лекарственная форма
tablet, 100 mg
Опыт использования
Protease inhibitor licensed in Japan and South Korea to treat chronic pancreatitis. In vitro experiments found it blocks a mechanism SARS-Cov-2 uses to enter human cells. As of early April, an estimated 180 COVID-19 patients aged 18-110 were being recruited at nine locations in Denmark for a phase 2a trial that will examine 30-day changes in disease severity and mortality, with results expected by December 2020. The University of Tokyo also announced plans for a trial of camostat mesylate and a related drug, nafamostat mesylate, starting as early as April 2020.
Публикации COVID-19
Trials. 2019 Aug 14;20(1):501. DOI: 10.1186/s13063-019-3606-y.
Клинические исследования
1.
Название протокола
Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection
Дата начала и окончания КИ
June 1, 2020 - December 31, 2021
Название организации, проводящей КИ
Heinrich-Heine University, Duesseldorf
Страны
Germany
Фаза
IV
Кол-во пациентов
334
2.
Название протокола
The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial
Дата начала и окончания КИ
April 30, 2020 - May 31, 2021
Название организации, проводящей КИ
Yale University
Страны
USA
Фаза
IIa
Кол-во пациентов
114
3.
Название протокола
An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus
Дата начала и окончания КИ
April 11, 2020 - December 11, 2020
Название организации, проводящей КИ
Sheba Medical Center
Страны
Israel
Фаза
III
Кол-во пациентов
250
4.
Название протокола
The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial
Дата начала и окончания КИ
March 31, 2020 - May 1, 2021
Название организации, проводящей КИ
University of Aarhus
Страны
Denmark
Фаза
IIa
Кол-во пациентов
180